1. Donor Lymphocyte Infusion for the Treatment of Relapsed Acute Myeloid Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Analysis by the Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation 
Akiyoshi Takami, Shingo Yano, Hiroki Yokoyama, Yachiyo Kuwatsuka, Takuhiro Yamaguchi, Yoshinobu Kanda, Yasuo Morishima, Takahiro Fukuda, Yasushi Miyazaki, Hirohisa Nakamae, Junji Tanaka, Yoshiko Atsuta, Heiwa Kanamori 
Biology of Blood and Marrow Transplantation 
Volume 20, Issue 11, Pages (November 2014)
DOI: /j.bbmt
Copyright © 2014 American Society for Blood and Marrow Transplantation Terms and Conditions

2. Figure 1
Survival after DLI according to the prognostic groups. Group 1 had a CR at DLI, regardless of the interval from HSCT to relapse (n = 11). Group 2 had a longer interval (≥5 months) from HSCT to relapse, but was not in CR at DLI (n = 51). Group 3 included the other patients (n = 81).
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2014 American Society for Blood and Marrow Transplantation Terms and Conditions